open access to scientific and medical research
From submission to first editorial decision.
From editorial acceptance to publication.
*Business days (Mon-Fri)
The above percentage of manuscripts have been rejected in the last 12 months.
Open access peer-reviewed scientific and medical journals.
Dove Medical Press is a member of the OAI.
Bulk reprints for the pharmaceutical industry.
We offer real benefits to our authors, including fast-track processing of papers.
Register your specific details and specific drugs of interest and we will match the information you provide to articles from our extensive database and email PDF copies to you promptly.
Back to Journals » Cancer Management and Research » Volume 13
Novel lncRNA LINC01614 Facilitates Bladder Cancer Proliferation, Migration and Invasion Through the miR-217/RUNX2/Wnt/β-Catenin Axis
Authors Wang Z, Yan H, Cheng D , Xu L, Shen T, Chen Y, Han R, Xue Y
Received 18 July 2021
Accepted for publication 18 October 2021
Published 9 November 2021 Volume 2021:13 Pages 8387—8397
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Bilikere Dwarakanath
Zhen Wang,* Huilin Yan,* Dingcai Cheng, Lei Xu, Tianming Shen, Yi Chen, Rongbo Han, Yanshi Xue
Department of Urology, Taixing People’s Hospital, Taixing City, 225400, Jiangsu Province, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yanshi Xue; Rongbo Han
Department of Urology, Taixing People’s Hospital, No. 1 Changzheng Road, Taixing City, 225400, Jiangsu Province, People’s Republic of China
Tel +86 523-87656001
Email [email protected]; [email protected]
Background: LncRNA plays a vital role in tumorigenesis and development. This study aimed to explore the novel lncRNA affecting bladder cancer progression.
Methods: The open-access data of bladder cancer patients, including transcriptome profiles and corresponding clinical information were all obtained from The Cancer Genome Atlas database. All the statistical analysis were performed using R software, SPSS and GraphPad Prism 8. CCK8, colony formation, apoptosis detection and tumorigenicity assay were used to assess cell proliferation ability. Transwell assay and wound-healing assay were used to evaluate cell metastasis potential.
Results: Our result showed that the lncRNA LINC01614 was highly expressed in bladder cancer tissue and cell lines. Meanwhile, patients with high LINC01614 expression level tend to have poor clinical features and shorter survival time. Further experiments demonstrated that the inhibition of LINC01614 could significantly hamper the proliferation and invasion of bladder cancer cells. Then, we found that the LINC01614 could regulate RUNX2 expression through miR-137. GSEA analysis indicated that the Wnt/β-catenin signaling pathway might be the downstream pathway of LINC01614. Further experiments showed that the LINC01614 act as an oncogene in bladder cancer partly depending on the RUNX2/Wnt/β-catenin axis, making it an underlying therapeutic target.
Conclusion: In all, LINC01614 facilitates bladder cancer cells proliferation, migration and invasion through the miR-217/RUNX2/Wnt/β-catenin axis.
Keywords: LINC01614, bladder cancer, lncRNA, Wnt/β-catenin
Bladder cancer is the ninth prevalent malignant tumor and responsible for about 570,000 newly diagnosed bladder cancer cases and 210,000 deaths worldwide in 2020.1,2 Overall, nonmuscle-invasive bladder urothelial carcinoma accounts for approximately three-quarters of bladder cancer and the others are muscle-invasive bladder cancer.3 Despite many rapid advances that have been made in the diagnostic modalities and standard treatments of bladder cancer patients, the recurrence and death rate remains unsatisfactory and the 5-year overall survival rate is only 50–60%.4 Therefore, it is essential to explore more effective targets as tumor biomarkers to predict prognosis and guide therapy.
Long noncoding RNA (lncRNA), located in the nucleus or cytoplasm, is a noncoding RNA with a length of more than 200 nucleotides.5 Accumulating evidence has revealed that lncRNA expression changes with the specific life process, which serves as the regulator of mRNA and protein.6 More and more attention has been focused on the link between lncRNA and tumor initiation, maintenance and metastasis.7 For example, Wu et al demonstrated that the lncRNA lncHDAC2 was highly expressed in hepatocellular carcinoma and played a critical role in promoting tumor progression through activating Hedgehog signaling.8 A recent study revealed that the lncRNA MALAT1 could interact and inactivate the transcription factor TEAD to prevent the link between TEAD and its co-activator YAP, thereby inhibiting breast cancer metastasis.9 Moreover, Dong et al indicated that the lncRNA TINCR activated by H3K27 acetylation could promote Trastuzumab resistance and epithelial-mesenchymal transition in breast cancer.10 In breast cancer, Vishnubalaji et al demonstrated that the LINC01614 was an adverse prognosis marker, which was regulated by TGF-β and FAK signaling.11 Wang et al found that the LINC01614 was up-regulated in glioma and could promote cancer progression through miR-383/ADAM12 axis.12 Another aspect, Liu et al revealed that LINC01614 might inhibit lung cancer through miR-217/FOXP1 axis.13 Thus, the potential role of lncRNA might bring novel insights for the diagnosis and treatment of bladder cancer.
The rapid development of next-generation has produced large volumes of genomic data, which provides excellent convenience for researchers. Our study first identified LINC01614 as the interesting gene due to its clinical correlation and high expression level in bladder cancer based on the data obtained from The Cancer Genome Atlas (TCGA) database. Further experiments showed that the knockdown of LINC01614 could significantly inhibit the progression of bladder cancer. Meanwhile, we found this cancer-promoting effect might partly rely on the downstream RUNX2/Wnt/β-catenin axis. In all, our data demonstrated that LINC01614 might be a promising therapeutic target for bladder cancer.
The public gene-expression profile data and clinical information of bladder cancer were downloaded from the TCGA-GDC (https://portal.gdc.cancer.gov/). All the transcript data were annotated using the reference file “Homo_sapiens.GRCh38.gtf” obtained from the Ensembl website (http://asia.ensembl.org/index.html). Before analysis, the data were preprocessed with the following steps: 1) missing value completion; 2) data normalization; 3) excluding unqualified samples. Gene Set Enrichment Analysis (GSEA) was used to perform to investigate the biological pathway difference between high and low LINC01614 patients. The reference gene set was “Hallmark.v7.4.gmt”. The input data of GSEA analysis has been uploaded in figshare website (https://figshare.com/articles/dataset/GSEA/16746517).
The bladder cancer tissue and matched normal tissue were all collected from Taixing People’s Hospital. All the patients have signed a written informed consent form. The Ethics committee of Taixing People’s Hospital approved the protocol of this study before beginning. Four bladder cancer cell lines (5637, J82, RT4 and T24) and one normal bladder epithelial cell (SV-HUC-1) were purchased from the Cell Bank of Culture of the Chinese Academy of Sciences and routinely maintained in our lab with 37°C and 5% CO2. This study was performed in accordance with the principles of the Declaration of Helsinki.
RNA extraction was performed when cells were grown to a density of 80% confluence. In brief, total RNA was extracted using an RNA extraction kit (Invitrogen) and then reverse transcribed into cDNA. A SyBr Green PCR system was used to detect PCR amplicons. The primers used were as follows: LINC01614, forward primer, 5ʹ-AGAGCCAAGTTCTAAAGG-3ʹ, reverse primer: 5ʹ-AATGTGCGATAGTTCAGTC-3ʹ; RUNX2, forward primer, 5ʹ-TGGTTACTGTCATGGCGGGTA-3ʹ, reverse primer, 5ʹ-TCTCAGATCGTTGAACCTTGCTA-3ʹ.
The protein extraction was conducted when cells were grown to a density of 100% confluence. In brief, cells were added with RIPA lysis buffer and then shocked on the ice for 2h. After frozen at −80 °C overnight, the mixture was centrifuged 30 min at 4 °C and the protein was drawn from the supernatant. The protein mixed with 1× loading buffer was loaded onto 10% SDS-PAGE gel and then transferred to a nitrocellulose membrane for further exposure. The primary antibodies were purchased from Proteintech (GSK3B polyclonal antibody, phospho-Gsk3b polyclonal antibody, betacatenin polyclonal antibody, C-MYC polyclonal antibody, beta actin polyclonal antibody).
The LINC01614 knockdown, RUNX2 overexpressed and corresponding control plasmid were synthesized by Synthgene (China). Lipofectamine 3000 (Thermo Fisher, USA) was used for cell transfection following the manufacturer’s protocol. The shRNA sequence of LINC01614 for cell transfection were as follows: shRNA#1: 5ʹ-CACATGACATAATCTGGGTTCTTTA-3ʹ; shRNA#2: 5ʹ-GGACAATGAAGACTGAACT-3ʹ; shRNA#3: 5ʹ-GGACTTCAGACACGGAGAA-3ʹ.
Cells were resuspended and seeded into a 96-well plate. CCK8 assay was performed using a CCK8 kit (Dojindo, Shanghai, China). In brief, cells that were added with CCK8 reagent were then incubated for 2 hours. The absorbance of 450nm reflecting the cell proliferation activity was measured at 0, 24, 48 and 72h time points.
Cells were resuspended and seeded into a six-well plate with 500 cells per well. The medium was changed every 4 days. After that for 12 days, cells were fixed with formaldehyde and stained with crystal violet for counting.
Cell apoptosis was assessed by flow cytometry assay with Annexin V/propidium iodide (PI) staining. Cells were resuspended with 1× binding buffer. FACSCalibur cytometer (BD Biosciences) was then used to aspirate cells and perform analysis. FlowJo software was used for data processing.
An EdU labeling kit (Beyotime) was used to perform EdU assay to evaluate the DNA synthesis in cells. In brief, cells were incubated with EdU solution for 2 hours and then followed a set of steps according to the kit instructions. After stained with fluorescent and DAPI, cells were observed and photographed by fluorescence microscopy.
The transwell chambers separate the 24-well plate into the upper chamber and lower chamber. In brief, 200 µl serum-free conditioned medium mixed with 2×104 cells. The lower chamber was added with a 600 µl medium containing 20% fetal bovine serum. After that for 24h, the chamber was removed. Cells were fixed with formaldehyde and stained with crystal violet for counting.
Wound healing assay was conducted when the cells were grown to a density of 100% confluence at a six-well plate. A 200-µl pipette tip was used to make scratches. Then, the cells were added with 1mL serum-free conditioned medium. The time points for observing were set as 0h and 24h.
Human T24 xenografts were established by subcutaneously inoculating 5×106 cells resuspended in PBS into BALB/c nude mice (5–8 weeks of age). These mice were purchased from the Nanjing Animal Center and randomly divided into sh-NC and sh-LINC01614 group. On 7–8 weeks of age, all the mice were sacrificed, and tumors were excised.
The Cy3-labeled LINC01614 probe was designed and purchased from Jima Com (Shanghai, China). In brief, T24 cells were plated and incubated overnight. Then, the cells were fixed with 100 µl 4% paraformaldehyde for 15 min at room temperature. According to the protocol of RNA FISH probe kit purchased from Jima Com (Shanghai, China), the probes were diluted (1:50), denatured, balanced and added to cells at 37 °C overnight. Finally, cell nuclei were counterstained with DAPI–Antifade. LINC01614 FISH probe used was 5‘-CTCCTTCCTGAACTTACTTGTCTGC-3ʹ.
All the statistical analyses were performed using the R software, SPSS and GraphPad Prism 8. Student’s T-test was used for the data meeting the normal distribution, and Mann–Whitney U-test was used for the data meeting the non-normal distribution. P-value was two-sided and less than 0.05 was regarded as statistically significant.
Firstly, we performed differential expression analysis with the threshold of |log2FC| >2 and adj.P.value <0.05 to identify differentially expressed lncRNAs between normal and bladder cancer tissue, in which 324 lncRNAs were down-regulated and 428 lncRNAs were up-regulated (Figure 1A). To identify cancer-promoting lncRNAs, we refined the screening conditions with tumorMean >2 and HR >1. Finally, four lncRNAs AC099850.3, LINC01614, MNX1-AS1, AC006329.1 were identified (Figure 1B). Among these, the lncRNA LINC01614 has been reported to promote cancer progression in other cancers.11–13 However, it has not been mentioned in bladder cancer. Therefore, the lncRNA LINC01614 aroused our interest and was chosen for further research. Next, we comprehensively analyzed the LINC01614 expression level in the TCGA-BLCA project, including 19 normal and 414 tumor samples. The results showed a higher expression level of LINC01614 in all samples and 19 paired samples (Figure 1C and D). Also, we observed that LINC01614 was highly expressed in our own 16 paired bladder cancer tissue (Figure 1E). At cell level, LINC01614 was also elevated in four bladder cancer cell lines (5637, J82, RT4 and T24) compared with normal bladder epithelial cells (SV-HUC-1) (Figure 1F). Next, we explored the correlation between LINC01614 and clinical features, including age, gender, clinical stage, grade and prognosis. Interestingly, we found that older patients might have a higher LINC01614 expression, aligned to the morbidity pattern of bladder cancer (Figure 2A). However, no significant difference was observed in male and female patients (Figure 2B). To be noted, we found that the LINC01614 tends to be highly expressed in patients with worse clinical features (High grade vs Low grade; Stage III–IV vs I–II; T3-4 vs T1-2; N1-2 vs N0; M1 vs M0) (Figure 2C–G). Furthermore, Kaplan–Meier survival curves demonstrated that the patients with high LINC01614 expression had a shorter survival time compared with those with low LINC01614 expression (Figure 2H).
Figure 1 LncRNA LINC01614 was up-regulated in bladder cancer tissue and cell lines.
Abbreviation: TCGA, The Cancer Genome Atlas.
Notes: (A) Differential expression analysis with the threshold of logFC >2 and adj.P <0.05 to identify differentially expressed lncRNAs between normal and bladder cancer tissue; (B) intersection with the lncRNAs meeting logFC >2, adj.P <0.05, tumorMean >2 and HR > 1 identified four lncRNAs; (C) LINC01614 was up-regulated in bladder cancer tissue (TCGA-BLCA, 19 normal tissue and 414 tumor tissue), ****P < 0.0001; (D) LINC01614 was up-regulated in paired bladder cancer tissue (TCGA-BLCA, 19 normal tissue and paired 19 tumor tissue), ****P < 0.0001; (E) LINC01614 was up-regulated in 16 paired bladder cancer tissue, ****P < 0.0001; (F) LINC01614 was up-regulated in bladder cancer cell lines, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Figure 2 LINC01614 was correlated with poor clinical parameters.
Notes: (A) The LIN01614 expression level in different age groups (<65 vs ≥65), ****P < 0.0001; (B) the LIN01614 expression level in male and female groups (female vs male), NS. P> 0.05; (C) the LIN01614 expression level in different grade groups (low-grade vs high-grade), ****P < 0.0001; (D) the LIN01614 expression level in different clinical stage groups (stage I–II vs stage III–IV), ****P < 0.0001; (E) the LIN01614 expression level in different Tstage groups (T1-2 vs T3-4), ****P < 0.0001; (F) the LIN01614 expression level in different Nstage groups (N0 vs N1-2), ****P < 0.0001; (G) the LIN01614 expression level in different Mstage groups (M0 vs M1), *P < 0.05; (H) Kaplan–Meier survival curve showed that the patients with high LINC01614 expression tend to have aworse prognosis.
To further explore the biological role of LINC01614 in bladder cancer, we performed cell transfection to knockdown endogenous LINC01614 expression, whose efficiency was validated by qRT-PCR (Figure 3A and B). CCK8 assay revealed that the cells with LINC01614 knockdown had a lower absorbance at 450nm, indicating that the inhibition of LINC01614 could hamper cell proliferation activity (Figure 3C and D). Meanwhile, colony formation assay showed that the cells in the knockdown interference group significantly decreased the colony number (Figure 3E). Another aspect, flow cytometry assay indicated that the inhibition of LINC01614 could remarkably increase the cell apoptosis rate (Figure 3F). Also, we found that tumor-forming ability in mice bearing with sh-LINC01614 was remarkably decreased compared with the control sh-NC T24 cells (Figure 3G).
Figure 3 LINC01614 promote the cell proliferation of bladder cancer.
Notes: (Aand B) qRT-PCR was used to validate the transfection efficiency of LINC01614, **P < 0.01, ***P < 0.001; (Cand D) CCK8 assay was performed in the control and LINC01614 knockdown cells, **P < 0.01; (E) colony formation assay was performed by in the control and LINC01614 knockdown cells, ***P < 0.001; (F) flow cytometry assessing cell apoptosis was conducted in the control and LINC01614 knockdown cells, ***P < 0.001; (G) invivo tumor-forming experiment was performed by in the control and LINC01614 knockdown group, ***P < 0.001.
We further explore whether LINC01614 could promote cell invasion. Transwell assay showed that LINC01614 silencing could significantly inhibit cell invasion and migration ability of bladder cancer cells (Figure 4A and B). Meanwhile, the wound healing assay showed that the scratch width narrowed significantly in the LINC01614 knockdown group in 24h (Figure 4C).
Figure 4 LINC01614 facilitates cell metastatic potential of bladder cancer.
Notes: (Aand B) Downregulation of LINC01614 reduced the number of invasion and migration cells in the transwell assay, ***P < 0.001; (C) wound-healing assay performed between control and LINC01614 knockdown cells, ***P < 0.001.
GSEA analysis showed that the LINC01614 might be involved in the activation of Wnt/β-catenin signaling pathway (Figure 5A). Therefore, we performed Western blotting assay to explore the key molecular change of the Wnt/β-catenin signaling pathway (p-GSK-3β, GSK-3β, β-catenin and c-myc). The result demonstrated that the inhibition of LINC01614 could significantly decrease the protein level of p-GSK-3β, β-catenin and c-myc, suggesting that LINC01614 could upregulate the Wnt/β-catenin pathway activity (Figure 5B).
Figure 5 LINC01614 affect the activity of the Wnt/β-catenin signaling pathway.
Notes: (A) GSEA analysis between high and low LINC01614 patients showed that the Wnt/β-catenin signaling pathway might be involved in the biological role of LINC01614; (B) knockdown of LINC01614 inhibits the activity of Wnt/β-catenin pathway.
Based on the expression profile data in TCGA, we screened the mRNA with a striking correlation with LINC01614 (|Cor > 0.3| and P < 0.01). In addition, we noticed that the gene RUNX2 reported promoting bladder cancer progression was significantly positively correlated with LINC01614 (Figure 6A and B, Cor = 0.52, P < 0.001).14 Moreover, we found that the patients with high RUNX2 expression might be associated with a worse prognosis and clinical features (Figure 6C–F). FISH assay showed that the LINC01614 was mainly localized in the cytoplasm, indicating that it may act through a competing endogenous RNA mechanism (Figure 6G). Furthermore, the intersection of Starbase and LncBase v2 identified two miRNA, miR-217 and miR-6807-3p, which might interact with LINC01614 (Figure 6H). qPCR results indicated that LINC01614 could regulate RUNX2 expression through miR-217, but not miR-6807-3p (Figure 6I–L).
Figure 6 Identification of RUNX2 as a target gene of LINC01614.
Abbreviation: FISH, fluorescence insitu hybridization.
Notes: (A) Identification of the genes significantly correlated with LINC01614 with the threshold of |Cor > 0.3| and P< 0.01; (B) RUNX2 was positively correlated with LINC01614 (r= 0.52, P< 0.001); (C) Kaplan–Meier survival curve showed that the patients with high RUNX2 expression was associated with aworse prognosis; (D) the RUNX2 expression level in different clinical stage groups (stage I–II vs stage III–IV), ****P < 0.0001; (E) the RUNX2 expression level in different Tstage groups (T1-2 vs T3-4), ****P < 0.0001; (F) the RUNX2 expression level in different Nstage groups (N0 vs N1-2), ****P < 0.0001; (G) FISH assay showed that LINC01614 was mainly localized in the cytoplasm; (H) the intersection of Starbase and LncBase v2 identified two miRNA, miR-217 and miR-6807-3p; (I–L) qPCR results indicated that LINC01614 could regulate RUNX2 expression through miR-217, but not miR-6807-3p, NS. P> 0.05, ***P < 0.001.
We further overexpressed RUNX2 in LINC01614 knockdown cells to explore the underlying association between RUNX2 and LINC01614, whose transfection efficiency was validated by qRT-PCR (Figure 7A). CCK8 and colony formation assay showed that the inhibition of LINC01614 could significantly hamper the cell proliferation ability of bladder cancer cells, and this effect might be partly reversed by RUNX2 overexpression (Figure 7B and C). Transwell assay also indicated that the knockdown of LINC01614 remarkably reduced the invasion and migration cells, which was antagonized by overexpression of RUNX2 (Figure 7D). Same conclusion was also observed in the EdU assay that RUNX2 might reverse the anti-cancer effect brought by the knockdown of LINC01614 to some extent (Figure 7E). Considering the fact that we proved the Wnt/β-catenin signaling pathway to be the downstream pathway of LINC01614, we therefore assessed the change of the Wnt/β-catenin molecular marker in sh-NC, sh-LINC01614 and sh-LINC01614 + RUNX2-OE cells. Western blotting demonstrated that the protein level of p-GSK-3β, β-catenin and c-myc were decreased in the LINC01614 knockdown cells, but rescued when the RUNX2 was overexpressed (Figure 7F–H).
Figure 7 LINC01614 promote bladder cancer progression through RUNX2/Wnt/β-catenin axis.
Notes: (A) The RUNX2 expression in sh-LINC01614 and sh-LINC01614+RUNX2-OE cells, ***P < 0.001; (B) CCK8 assay was performed in sh-NC, sh-LINC01614 and sh-LINC01614+RUNX2-OE cells, **P < 0.01; (C) colony formation assay was performed in sh-NC, sh-LINC01614 and sh-LINC01614+RUNX2-OE cells, ***P < 0.001; (D) transwell assay was conducted in sh-NC, sh-LINC01614 and sh-LINC01614+RUNX2-OE cells, ***P < 0.001; (E) EdU assay was performed in the sh-NC, sh-LINC01614 and sh-LIC01614+RUNX2-OE cells, ***P < 0.001; (F–H) Western blot was used to detect the marker of Wnt/β-catenin pathway and RUNX2 in different groups, NS. P> 0.05, ***P < 0.001.
As the most common malignancy of the urinary tract, bladder cancer is a major cause of cancer-associated mortality worldwide.15 Although early diagnosis effectively improves patients’ survival, the disease heterogeneity of different stages worsen patients’ prognosis. Therefore, it is imperative to find a novel and effective tumor and prognosis biomarker for bladder cancer diagnosis and treatment.
With the advent of the human genome era, lncRNA has been widely reported to participate in the regulatory process of cell life, including metabolic regulation, epigenetics, molecular bridge, etc.16 Also, lncRNA plays a vital role in cancer tumorigenesis and development. For example, Logotheti et al revealed that the lncRNA SLC16A1-AS1 could promote bladder cancer progression by inducing metabolic reprogramming and co-activating E2F1.17 Ni et al identified a novel lncRNA uc.134 that was down-regulated in hepatocellular carcinoma.18 Meanwhile, they found that the lncRNA uc.134 could significantly hamper LAST1 degradation and ubiquitination mediated by CUL4A, thereby increasing Hippo kinase activity and inhibiting hepatocellular carcinoma progression.18 Marín-Béjar et al demonstrated that the lncRNA LINC-PINT was widely down-regulated in multiple cancer and had a highly conserved sequence element that was important for its function.19 More intensively, the conserved sequence mediates the interaction between lncRNA LINC-PINT and PRC2, which is essential for the repression of cancer-inhibiting signature of genes regulated by the transcription factor EGR1. In our study, the lncRNA LINC01614 was first identified to promote bladder cancer progression, which has not been previously reported. Our result showed that the lncRNA LINC01614 could be an underlying tumor and prognosis biomarker of bladder cancer.
Based on the expression profile data of TCGA, we identified the gene RUNX2 as a downstream gene of LINC01614. RUNX2 is a member of the RUNX family of transcription factors and encodes a nuclear protein with a runt DNA-binding domain.20 The aberrant expression pattern of RUNX2 has been observed in most solid tumors, indicating its close genetic association with initiation and progression.21,22 In papillary thyroid carcinoma, Sancisi et al found that the RUNX2 was controlled by Id1 and activated a gene list involved in the matrix degradation and cell invasion to facilitate cancer progression.23 In pancreatic cancer, Kayed et al indicated that TGF-beta1 and BMP2 regulated RUNX2 in an auto- and paracrine manner to affect tumor microenvironment, thereby promoting cancer progression.24 Moreover, a 5-year follow-up study showed that lung cancer patients with higher RUNX2 mRNA expression were associated with a worse prognosis.25 Meanwhile, multiple studies demonstrated that RUNX2 acts as an oncogene in bladder cancer through different genetic mechanisms, indicating its diverse effect patterns.14,26 Our result showed that LIN01614 positively regulated RUNX2 expression and partly dependent on RUNX2 to promote cancer progression, refining the function network of RUNX2 in bladder cancer.
Wnt/β-catenin signaling pathway is a critically important axis that affects the myriad biological processes throughout animal development.27 In parallel, abnormal Wnt/β-catenin activity was responsible for many pathological processes, including cancer initiation and progression.27 Yang et al indicated that LINC01133 regulated the activity of Wnt/β-catenin signaling through a competitive endogenous RNA (ceRNA) mechanism to inhibit gastric cancer progression.28 In breast cancer, Li et al showed that c-myc could interact with β-catenin and activate the Wnt/β-catenin downstream genes Cyclin D1 and Axin2 to influence breast cancer progression.29 Furthermore, accumulating evidence has strengthened the potential of anti-cancer drugs targeting the Wnt/β-catenin signaling pathway, for example, PORCN and FZD inhibitor.30 Our results proved that the LINC01614 might activate the Wnt/β-catenin pathway activity, indicating its potential to be a target for bladder cancer targeted therapy.
To the best of our knowledge, this study is the first study focused on the role of LINC01614 in bladder cancer. Here, we found that LINC01614 was up-regulated in the bladder cancer tissue and cell lines. Meanwhile, the high expression level of LINC01614 was associated with poor clinical features and a shorter survival time. In vitro experiments demonstrated that LINC01614 could remarkably facilitate bladder cancer proliferation and invasion. RUNX2 was then found positively correlated with LIN01614 in RNA level. Further experiments showed that the overexpression of RUNX2 could partly rescue the cancer-inhibiting effect brought by the LINC01614 knockdown. GSEA analysis and Western blot assay proved that the Wnt/β-catenin was the downstream pathway of LINC01614. Overall, our result showed that LINC01614 promotes bladder cancer progression through the RUNX2/Wnt/β-catenin axis, making it an underlying tumor biomarker and therapeutic target.
There is no funding to report.
The authors report no conflicts of interest in this work.
1. Lenis AT, Lec PM, Chamie K, Mshs MD. Bladder cancer: a review. JAMA. 2020;324(19):1980–1991. doi:10.1001/jama.2020.17598
2. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2(9):533–543. doi:10.1016/S1470-2045(01)00486-7
3. Babjuk M, Böhle A, Burger M, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017;71(3):447–461. doi:10.1016/j.eururo.2016.05.041
4. Racioppi M, D’Agostino D, Totaro A, et al. Value of current chemotherapy and surgery in advanced and metastatic bladder cancer. Urol Int. 2012;88(3):249–258. doi:10.1159/000335556
5. Cabili MN, Trapnell C, Goff L, et al. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev. 2011;25(18):1915–1927. doi:10.1101/gad.17446611
6. Satpathy AT, Chang HY. Long noncoding RNA in hematopoiesis and immunity. Immunity. 2015;42(5):792–804. doi:10.1016/j.immuni.2015.05.004
7. Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet. 2014;15(1):7–21. doi:10.1038/nrg3606
8. Wu J, Zhu P, Lu T, et al. The long non-coding RNA LncHDAC2 drives the self-renewal of liver cancer stem cells via activation of Hedgehog signaling. J Hepatol. 2019;70(5):918–929. doi:10.1016/j.jhep.2018.12.015
9. Kim J, Piao HL, Kim BJ, et al. Long noncoding RNA MALAT1 suppresses breast cancer metastasis. Nat Genet. 2018;50(12):1705–1715. doi:10.1038/s41588-018-0252-3
10. Dong H, Hu J, Zou K, et al. Activation of LncRNA TINCR by H3K27 acetylation promotes trastuzumab resistance and epithelial-mesenchymal transition by targeting MicroRNA-125b in breast cancer. Mol Cancer. 2019;18(1):3. doi:10.1186/s12943-018-0931-9
11. Vishnubalaji R, Shaath H, Elkord E, Alajez NM. Long non-coding RNA (lncRNA) transcriptional landscape in breast cancer identifies LINC01614 as non-favorable prognostic biomarker regulated by TGFβ and focal adhesion kinase (FAK) signaling. Cell Death Discov. 2019;5:109. doi:10.1038/s41420-019-0190-6
12. Wang H, Wu J, Guo W. SP1-mediated upregulation of lncRNA LINC01614 functions a ceRNA for miR-383 to facilitate glioma progression through regulation of ADAM12. Onco Targets Ther. 2020;13:4305–4318. doi:10.2147/OTT.S242854
13. Liu AN, Qu HJ, Yu CY, Sun P. Knockdown of LINC01614 inhibits lung adenocarcinoma cell progression by up-regulating miR-217 and down-regulating FOXP1. J Cell Mol Med. 2018;22(9):4034–4044. doi:10.1111/jcmm.13483
14. Zhao X, Ji Z, Xie Y, Liu G, Li H. MicroRNA-154 as a prognostic factor in bladder cancer inhibits cellular malignancy by targeting RSF1 and RUNX2. Oncol Rep. 2017;38(5):2727–2734. doi:10.3892/or.2017.5992
15. Dobruch J, Daneshmand S, Fisch M, et al. Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes. Eur Urol. 2016;69(2):300–310. doi:10.1016/j.eururo.2015.08.037
16. Qian X, Zhao J, Yeung PY, Zhang QC, Kwok CK. Revealing lncRNA structures and interactions by sequencing-based approaches. Trends Biochem Sci. 2019;44(1):33–52. doi:10.1016/j.tibs.2018.09.012
17. Logotheti S, Marquardt S, Gupta SK, et al. LncRNA-SLC16A1-AS1 induces metabolic reprogramming during bladder cancer progression as target and co-activator of E2F1. Theranostics. 2020;10(21):9620–9643. doi:10.7150/thno.44176
18. Ni W, Zhang Y, Zhan Z, et al. A novel lncRNA uc.134 represses hepatocellular carcinoma progression by inhibiting CUL4A-mediated ubiquitination of LATS1. J Hematol Oncol. 2017;10(1):91. doi:10.1186/s13045-017-0449-4
19. Marín-Béjar O, Mas AM, González J, et al. The human lncRNA LINC-PINT inhibits tumor cell invasion through a highly conserved sequence element. Genome Biol. 2017;18(1):202. doi:10.1186/s13059-017-1331-y
20. Komori T. Runx2, an inducer of osteoblast and chondrocyte differentiation. Histochem Cell Biol. 2018;149(4):313–323. doi:10.1007/s00418-018-1640-6
21. Manzotti G, Torricelli F, Donati B, Sancisi V, Gugnoni M, Ciarrocchi A. HDACs control RUNX2 expression in cancer cells through redundant and cell context-dependent mechanisms. J Exp Clin Cancer Res. 2019;38(1):346. doi:10.1186/s13046-019-1350-5
22. Fritz AJ, Hong D, Boyd J, et al. RUNX1 and RUNX2 transcription factors function in opposing roles to regulate breast cancer stem cells. J Cell Physiol. 2020;235(10):7261–7272. doi:10.1002/jcp.29625
23. Sancisi V, Borettini G, Maramotti S, et al. Runx2 isoform I controls a panel of proinvasive genes driving aggressiveness of papillary thyroid carcinomas. J Clin Endocrinol Metab. 2012;97(10):E2006–2015. doi:10.1210/jc.2012-1903
24. Kayed H, Jiang X, Keleg S, et al. Regulation and functional role of the Runt-related transcription factor-2 in pancreatic cancer. Br J Cancer. 2007;97(8):1106–1115. doi:10.1038/sj.bjc.6603984
25. Li H, Zhou RJ, Zhang GQ, Xu JP. Clinical significance of RUNX2 expression in patients with nonsmall cell lung cancer: a 5-year follow-up study. Tumour Biol. 2013;34(3):1807–1812. doi:10.1007/s13277-013-0720-4
26. Liu J, Yu X, Liu B, Yu H, Li Z. Phosphorylated MAPK14 promotes the proliferation and migration of bladder cancer cells by maintaining RUNX2 protein abundance. Cancer Manag Res. 2020;12:11371–11382. doi:10.2147/CMAR.S274058
27. Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell. 2012;149(6):1192–1205. doi:10.1016/j.cell.2012.05.012
28. Yang XZ, Cheng TT, He QJ, et al. LINC01133 as ceRNA inhibits gastric cancer progression by sponging miR-106a-3p to regulate APC expression and the Wnt/β-catenin pathway. Mol Cancer. 2018;17(1):126. doi:10.1186/s12943-018-0874-1
29. Li Y, Jin K, van Pelt GW, et al. c-Myb enhances breast cancer invasion and metastasis through the Wnt/β-Catenin/Axin2 pathway. Cancer Res. 2016;76(11):3364–3375. doi:10.1158/0008-5472.CAN-15-2302
30. Zhang Y, Wang X. Targeting the Wnt/β-catenin signaling pathway in cancer. J Hematol Oncol. 2020;13(1):165. doi:10.1186/s13045-020-00990-3
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.
© Copyright 2021 • Dove Press Ltd • software development by maffey.com • Web Design by Adhesion
The opinions expressed in all articles published here are those of the specific author(s), and do not necessarily reflect the views of Dove Medical Press Ltd or any of its employees.
Dove Medical Press is part of Taylor & Francis Group, the Academic Publishing Division of Informa PLC
Copyright 2017 Informa PLC. All rights reserved. This site is owned and operated by Informa PLC ( “Informa”) whose registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36